Format

Send to

Choose Destination
Mol Cell Oncol. 2015 Jan 23;2(3):e988508. doi: 10.4161/23723556.2014.988508. eCollection 2015 Jul-Sep.

TRF2 acts as a transcriptional regulator in tumor angiogenesis.

Author information

1
Institut for Research on Cancer and Aging; Nice (IRCAN); University of Nice Sophia-Antipolis ; CNRS UMR7284/INSERM U1081 ; Faculty of Medicine ; Nice, France.
2
Institut for Research on Cancer and Aging; Nice (IRCAN); University of Nice Sophia-Antipolis; CNRS UMR7284/INSERM U1081; Faculty of Medicine; Nice, France; Department of Pathology; Nice, France.
3
Institut for Research on Cancer and Aging; Nice (IRCAN); University of Nice Sophia-Antipolis; CNRS UMR7284/INSERM U1081; Faculty of Medicine; Nice, France; Department of Medical Genetics; CHU; Nice, France.

Abstract

We recently showed that telomeric repeat-binding factor 2 (TRF2) regulates gene expression to promote angiogenesis. We found that TRF2 is highly expressed in tumor vessels and transcriptionally activates platelet-derived growth factor receptor β to promote endothelial cell angiogenic properties independently of its function in telomere protection. This work identifies TRF2 as a promising dual target for cancer therapy.

KEYWORDS:

Wilms’ tumor suppressor WT1; telomeres; telomeric repeat-binding factor 2 (TRF2); transcriptional regulation; tumor angiogenesis

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center